GlassScriptPhysician profile
Michelle M Murray
NPI 1467497420
$6,318.03
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $642 · 2021: $1,288 · 2022: $1,215 · 2023: $1,760 · 2024: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,548.78 | 2019-2024 | |
| Glaxosmithkline, LLC. | $626.37 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $581.57 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $559.34 | 2020-2024 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $426.62 | 2019-2022 | |
| Amgen INC. | $320.58 | 2019-2024 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.77 | 2019-2024 | Jardiance |
| Pfizer INC. | $268.45 | 2019-2024 | |
| Astellas Pharma US INC | $164.52 | 2020-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $156.94 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $154.36 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $137.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $132.95 | 2019-2024 | Spravato |
| Exact Sciences Corporation | $99.98 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $90.52 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $77.82 | 2019-2024 | Vaxelis, Gardasil 9, M-M-R II |
| Amarin Pharma, INC. | $77.52 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $70.00 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.73 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $62.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.80 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.32 | 2022 | |
| Genentech USA, INC. | $37.25 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.33 | 2023 | |
| Bausch Health US, LLC | $36.11 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $35.66 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $26.33 | 2024 | Auvelity |
| Abbott Laboratories | $22.37 | 2023 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $21.52 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.06 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.83 | 2024 | Gvoke Hypopen |
| Medtronic, INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.